Clinical trials of the efficacy and safety of cancer therapeutics that target eIF4E have been carried out (Graff et al, 2008) and some toxicity has been reported (O'Donnell et al, 2008; Tabernero et al, 2008). This evidence concerns the gene EIF4E and cancer.